Clinical Trial Update: 24-hour IOP-lowering Effect of Brimonidine 0.1% [Phase 4]

View source ↗

Summary

A Phase 4 trial assessing the 24-hour intraocular pressure-lowering effect of brimonidine 0.1% in open-angle glaucoma and ocular hypertension has completed, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• ALPHAGAN P (BRIMONIDINE TARTRATE)

Snippet

Sponsor: Allergan | Conditions: Open-angle Glaucoma, Ocular Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2011-11-24